CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 75 filers reported holding CUE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.21 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $143 | -47.6% | 62 | 0.0% | 0.00% | – |
| Q2 2023 | $273 | +35.1% | 62 | 0.0% | 0.00% | – |
| Q1 2023 | $202 | -96.6% | 62 | -97.0% | 0.00% | – |
| Q4 2022 | $6,000 | -94.4% | 2,062 | -95.7% | 0.00% | – |
| Q3 2022 | $107,000 | +11.5% | 48,262 | +24.5% | 0.00% | – |
| Q2 2022 | $96,000 | -96.0% | 38,762 | +1.5% | 0.00% | -100.0% |
| Q1 2022 | $2,407,000 | +699.7% | 38,182 | +43.4% | 0.01% | +400.0% |
| Q4 2021 | $301,000 | -33.8% | 26,620 | -14.7% | 0.00% | 0.0% |
| Q3 2021 | $455,000 | +92.0% | 31,220 | +52.9% | 0.00% | 0.0% |
| Q2 2021 | $237,000 | +18.5% | 20,420 | +24.4% | 0.00% | – |
| Q1 2021 | $200,000 | +9900.0% | 16,420 | +13583.3% | 0.00% | – |
| Q4 2020 | $2,000 | 0.0% | 120 | 0.0% | 0.00% | – |
| Q3 2020 | $2,000 | -33.3% | 120 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | +50.0% | 120 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | – | 120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 1,915,219 | $23,959,000 | 5.70% |
| Prosight Management, LP | 906,569 | $11,341,000 | 5.24% |
| P.A.W. CAPITAL CORP | 140,000 | $1,751,000 | 1.54% |
| Voss Capital, LLC | 220,714 | $2,761,000 | 1.39% |
| Robertson Stephens Wealth Management, LLC | 484,000 | $6,054,000 | 1.26% |
| Slate Path Capital LP | 1,483,619 | $18,560,000 | 1.00% |
| Nantahala Capital Management | 2,506,772 | $31,360,000 | 0.97% |
| PRECEPT MANAGEMENT LLC | 150,000 | $1,877,000 | 0.76% |
| SANDERS MORRIS HARRIS LLC | 193,591 | $2,449,000 | 0.56% |
| Rock Creek Group, LP | 100,014 | $1,251,000 | 0.51% |